148 related articles for article (PubMed ID: 19245434)
1. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells.
Chamoto K; Takeshima T; Wakita D; Ohkuri T; Ashino S; Omatsu T; Shirato H; Kitamura H; Togashi Y; Nishimura T
Cancer Sci; 2009 May; 100(5):934-9. PubMed ID: 19245434
[TBL] [Abstract][Full Text] [Related]
2. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
3. Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma.
Yokouchi H; Chamoto K; Wakita D; Yamazaki K; Shirato H; Takeshima T; Dosaka-Akita H; Nishimura M; Yue Z; Kitamura H; Nishimura T
Clin Exp Metastasis; 2007; 24(7):533-40. PubMed ID: 17653821
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.
Geary SM; Lemke CD; Lubaroff DM; Salem AK
Cancer Immunol Immunother; 2011 Sep; 60(9):1309-17. PubMed ID: 21626029
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.
Yuan S; Qiao T; Chen W
Cancer Biother Radiopharm; 2011 Apr; 26(2):203-8. PubMed ID: 21539452
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
7. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy.
Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T
Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286
[TBL] [Abstract][Full Text] [Related]
8. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.
Zhang M; Yin T; Lu Y; Feng H
Med Sci Monit; 2016 Apr; 22():1309-17. PubMed ID: 27092689
[TBL] [Abstract][Full Text] [Related]
9. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
11. Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma.
Chen X; Liu Z; Huang Y; Li R; Zhang H; Dong S; Ge C; Zhang Z; Wang Y; Wang Y; Xue Y; Li Z; Song X
Autoimmunity; 2014 Feb; 47(1):46-56. PubMed ID: 24191684
[TBL] [Abstract][Full Text] [Related]
12. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.
Alteber Z; Azulay M; Cafri G; Vadai E; Tzehoval E; Eisenbach L
Cancer Immunol Immunother; 2014 Apr; 63(4):369-80. PubMed ID: 24452202
[TBL] [Abstract][Full Text] [Related]
13. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.
Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Kowalczyk A; Kallen KJ; Huber SM
Radiat Oncol; 2014 Aug; 9():180. PubMed ID: 25127546
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M
Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800
[TBL] [Abstract][Full Text] [Related]
15. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
17. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
[TBL] [Abstract][Full Text] [Related]
20. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
